Danske Bank
CLRB icon

Danske Bank’s Cellectar Biosciences CLRB Stock Holding History

Danske Bank’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4 Hold
2
– – ﹤0.01% 1094
2026
Q2 		$6 Hold
2
– – ﹤0.01% 1083
2026
Q1 		$5 Hold
2
– – ﹤0.01% 1102
2025
Q4 		$6 Hold
2
– – ﹤0.01% 1495
2025
Q3 		$11 Hold
2
– – ﹤0.01% 1415
2025
Q2 		$14 Buy
+2
New +$17 ﹤0.01% 1461

Other funds holding CLRB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Key Financial Inc
Key Financial Inc West Chester, Pennsylvania $614M AUM 14.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Danske Bank's CLRB Position: Q3 2026 in Review

Danske Bank held its Cellectar Biosciences (CLRB) position steady in Q3 2026 at 2 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #1094.

Danske Bank first reported a position in CLRB in Q2 2025 and has held it in 6 quarters since. The position peaked at $14 in Q2 2025. 9 funds tracked by Wall St. Rank hold CLRB as of Q3 2026.

  • Danske Bank held 2 shares of Cellectar Biosciences worth $4 as of Q3 2026.
  • Danske Bank left its Cellectar Biosciences share count unchanged in Q3 2026.
  • Cellectar Biosciences made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #1094 holding.
  • Danske Bank first reported a position in Cellectar Biosciences in Q2 2025 and has held it in 6 quarters since.
  • Danske Bank's Cellectar Biosciences position peaked at $14 in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.